Introduction {#s1}
============

Sphingolipids are structural and functional components of biological membranes [@pone.0090362-Ipatova1], and their metabolites, including sphinganine, ceramide, sphingosine, and sphingosine 1-phosphate (S1P), have emerged as critical players in a number of fundamental biological processes. For example, these metabolites act as bioactive mediators in various cellular processes, including survival, proliferation, differentiation, and apoptosis [@pone.0090362-Ricci1], [@pone.0090362-Cuvillier1]. Moreover, sphingolipids are known to be involved in almost every type of disease [@pone.0090362-Zheng1]. They are reported to have regulation effect n cancer pathogenesis, progression, angiogenesis, proliferation, migration, inflammation, drug resistance, and cell death (apoptosis, necrosis, autophagy, and anoikis) [@pone.0090362-Selvam1], [@pone.0090362-Hannun1]. Sphingosine kinases (SphKs), including sphingosine kinase type 1 (SK1/SphK1) and sphingosine kinase type 2 (SK2/SphK2), catalyze the phosphorylation of sphingosine to S1P and are crucial regulators of the balance among ceramides, sphingosine, and S1P [@pone.0090362-Shida1]. Unlike SK2, SK1 does not contain any transmembrane domains. In addition, their tissue distributions differ in human beings, as well as in animals [@pone.0090362-Blondeau1]--[@pone.0090362-Murate1], and their opposing functions in sphingolipid metabolism have also been reported [@pone.0090362-Maceyka1]. Specifically, SK1 has become a cancer research hotspot in cancer and has recently been considered a bona fide oncogene [@pone.0090362-Vadas1].

Much evidence has shown that SK1 can be detected in tumor tissues; notably, SK1 was reported to be overexpressed in most studies [@pone.0090362-Akao1]--[@pone.0090362-Johnson1]. Immunohistochemistry (IHC), polymerase chain reaction (PCR), and western blotting (WB) are usually used in such studies. The data showed that relative to paired non-cancer tissues, elevated SK1 expression ranges from 2- to 8-fold at both the mRNA and protein levels in some cancers, including breast, lung, ovarian, stomach, and colon cancers. Meanwhile, some studies found that SK1 overexpression might be related to cancer metastasis, reduced survival time, and poor prognosis [@pone.0090362-Van1], [@pone.0090362-Li1]. Therefore, SK1 was suggested as a novel biomarker of clinical prognosis in some cancers [@pone.0090362-Pyne1]. However, no systematic reviews or meta-analyses have discussed the role and clinical significance of SK1 in cancer. Therefore, we performed a meta-analysis to investigate the relationship between SK1 expression and various cancers and the possibility that SK1 might be used as a cancer biomarker.

Materials and Methods {#s2}
=====================

Search strategy and study selection {#s2a}
-----------------------------------

Electronic databases, including the English PubMed, EBSCO, ISI, OVID, ACS, and Cochrane Library databases and the Chinese VIP, Wan Fang, and China National Knowledge Infrastructure (CNKI) databases, and Google Scholar were searched for publications from inception to September 2013. The search keywords and terms were "sphingosine kinase type 1" OR "sphingosine kinase 1" OR "Sphk1" OR "Sphk-1" OR "SK1" OR "SK-1" OR "SK-I" AND "cancer" OR "tumor" OR "neoplasm" OR "carcinoma." Only Chinese- and English-language papers were included. All articles were imported into EndNote X6 software (Thomson Reuters Corporation, New York, NY, USA) to eliminate duplicates.

All titles and abstracts were read by 2 independent reviewers (Yun ZHANG and Yan WANG) to select eligible studies. Next, the full texts were independently read and carefully checked to exclude ineligible studies. Disagreements were resolved via consensus.

Study selection criteria {#s2b}
------------------------

The inclusion criteria for primary studies were as follows: (1) human studies; (2) cancer types and detection method were clearly described; and (3) SK1 expression was reported.

The exclusion criteria for primary studies can be summarized as follows: (1) reviews, abstracts, and case reports; (2) animal or cell studies; (3) no description of detection methods; (4) a total sample size \< 10; (5) a lack of SK1 expression data or the IHC, PCR, and WB results were only reported in figures; (6) the hazard ratios (HR) and 95% confidence intervals (CI) of survival analyses were not reported or could not be calculated from other data; and all articles with the data from the same patient population, except for the most recent report.

Data extraction {#s2c}
---------------

A data collection form was designed before extracting data. The final included articles were assessed independently by 2 reviewers (Yun ZHANG and Yan WANG). The extracted data included the first author, year of publication, and country; cancer types, specimen types, and detection methods; the number of patients in the experimental and control groups; the number of cancer, adjacent non-cancer, and benign samples and the number of SK1-positive (high expression or a score ≥ ++) and negative patients (low expression or a score of -- or +); the mRNA/protein expression levels in cancer and non-cancer tissues; the 5-year survival, overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS) outcomes and the follow-up duration. Among these, if the HR was not originally reported, we calculated or extracted this data according to the methods described by Tierney (2007) or Parmar (1998) [@pone.0090362-Parmar1], [@pone.0090362-Tierney1].

Statistical methods {#s2d}
-------------------

The Review Manager software (version 5.02 for Windows; The Cochrane Collaboration, 2009) was used for the meta-analysis, and STATA 12.0 software (StataCorp, College Station, TX, USA) was used to analyze the publication bias (Egger's test). According to the Review Manager Handbook, for dichotomous data such as the number of patients with SK1 positivity/high expression in cancer and non-cancer tissues, the odds ratios (OR) and 95% CI were combined to provide effective values. For continuous data such as SK1 activity, the standardized mean difference (SMD) and 95% CI were used to estimate effective values. For the association between SK1 and OS, 5-year survival was described as a HR and 95% CI. Statistical heterogeneity was examined with the Cochrane Q-test (significant at P \< 0.1) and *I* ^2^ value. When P \< 0.1 or *I* ^2^ \< 50%, a fixed-effect model was used; otherwise, a random-effect model was used. If necessary, a sensitive analysis was also performed to evaluate the influences of individual studies on the final effect. When some studies were omitted or subgroup analyses were adopted and if no decreases in heterogeneity were observed, the qualitative systematic review method was used to describe the results. All P values were 2-sided, and P \< 0.05 was considered significant.

Results {#s3}
=======

Search results and characteristics {#s3a}
----------------------------------

According to the inclusion criteria, 34 studies, including 11 Chinese articles and 23 English articles, were eligible for the final meta-analysis ([figure 1](#pone-0090362-g001){ref-type="fig"}) [@pone.0090362-Brizuela1]--[@pone.0090362-Johnson1], [@pone.0090362-Bayerl1]--[@pone.0090362-Ruckhaberle2]. The studies were published between 2005 and 2013. This analysis included 4,673 patients, 19 types of cancer from 7 countries, and 5 types of detection methods. The follow-up duration ranged from 30 months to 12 years. Seven studies were about breast cancer; 6 studies, colon cancer; and 4 studies, gastric cancer. The characteristics of the included studies are shown in [Table 1](#pone-0090362-t001){ref-type="table"}.

![Flow chart of identified eligible studies.](pone.0090362.g001){#pone-0090362-g001}

10.1371/journal.pone.0090362.t001

###### Main characteristics and results of the eligible studies.

![](pone.0090362.t001){#pone-0090362-t001-1}

  First author, year    Country   Ethnicity       Location of Cancer         Stage        Samples        No. pts(e/c)      Detection method     SK1 exp     Cut off   Follow up                HR estimation
  -------------------- --------- ----------- ---------------------------- ------------ -------------- ------------------- ------------------ ------------- --------- ----------- -----------------------------------------
  Eugen R. 2008         Germany   Caucasian             Breast             Hg I--III     microarray         171/968              IHC              Pr        AP\>843     60 m                5S 1.59(1.11--2.28)
  Eugen R.2013          Germany   Caucasian             Breast             Cs I--III        TMA               112                IHC              Pr         IRS≥6      120 m     5S 1.29(0.19--8.81) OS 1.24(0.24--6.33)
  Racheli E.R. 2010       UK      Caucasian             Breast             SBR I--III       RNA            20(20/20)             PCR             mRNA         NA         NA                         NA
  Zhang Y. 2010          China      Asian               Breast             Cs I--III        FFPE              77                 IHC              Pr         IRS≥4       NA                         NA
  Jan O. 2012             UK      Caucasian          Breast (ER-)          SBR I--III       TMA               140                IHC              Pr        Hs≥50%      140 m              OS 8.84(4.51--17.33)
  Jan O.2013              UK      Caucasian          Breast (ER+)          Cs I--III        FFPE              304                IHC              Pr        Hs≥50%      120 m     5S 1.84(0.97--3.49) OS 2.17(1.38--3.39)
  Carol W. 2010           UK      Caucasian          Breast (ER+)          SBR I--III       TMA               304                IHC              Pr         Hs≥2       144 m     5S 1.98(1.0--3.92) OS 1.80(1.10--2.93)
  Liu S.Q. 2012          China      Asian               Colon                Ds A-D      Fre/ FFPE         66(66/66)            IHC/WB            Pr         Ws≥2        NA                         NA
  Su Y.j.2012            China      Asian               Colon                Ds A-D      Fre/ FFPE            66              IHC/PCR/WB        mRNA/Pr      Ws≥2+       NA                         NA
  Toshihiko K. 2009       USA     Caucasian             Colon                  NA           TMA               94                 IHC              Pr        Hs≥25%       NA                         NA
  Jin H. 2010            China      Asian             Colorectal               NA           Fre            48(24/24)            PCR/WB          mRNA/Pr       NA         NA                         NA
  Roberta R. 2013        Italy    Caucasian           Colorectal               NA           FFPE              50                IHC/WB            Pr        Hs≥50%       NA                         NA
  Paweł K. 2010         Poland    Caucasian          Endometrial               NA        Fre/ blood        41(23/18)              Ra           Activity       NA         NA                         NA
  Jian Pan 2011          China      Asian             Esophageal             T0-T3      TMA/Fre/FFPE   124/30pair/12pair      TMA/IHC/WB          Pr        Hs≥25%      96 m      5S 2.60(1.93--3.51) OS 2.62(1.93--3.55)
  Liu Y. 2012            China      Asian             Esophageal             T0-T3          Fre               56                PCR/WB          mRNA/Pr       NA         NA                         NA
  Shang H.X. 2012        China      Asian              Gastric              Cs I-IV       Fre/FFPE         31(31/31)           PCR/IHC           mRNA        IRS≥6       NA                         NA
  Wen L.2009             China      Asian              Gastric              Cs I-IV       Fre/FFPE        185(175/10)         IHC/PCR/WB        mRNA/Pr      IRS≥6      140 m              5S 6.32(3.80--10.53)
  Zhuge Y.H. 2011        China      Asian              Gastric              Cs I-IV         Fre           246(206/40)            IHC              Pr         IRS≥4      60 m      5S 2.06(0.99--4.29) OS 2.06(0.99--4.28)
  Zhang L.J. 2013        China      Asian              Gastric                 NA           Fre              5pair              IHC/WB            Pr          NA         NA                         NA
  Guan H.Y. 2009         China      Asian               Glioma              Cs I-IV       FFPE/Fre           243/4             IHC/PCR            Pr         IRS≥8      60 m      5S 2.95(1.46--5.98) OS 2.95(1.46--5.98)
  Bao M.Y. 2011          China      Asian               Liver                  NA           Fre           100(50/50)             PCR             mRNA         NA         NA                         NA
  Brianna N.H.2013        USA     Caucasian             HNSCC                  NA           Fre               18              IHC/PCR/WB        mRNA/Pr       NA        30 m                OS 0.79(0.14--4.56)
  Keisuke S.2011          USA     Caucasian             HNSCC               Cs I--IV        TMA            95(78/17)             IHC            Protein     IRS≥1.5      NA                         NA
  Uttam K.S. 2010         USA     Caucasian             HNSCC               Cs I--IV      Fre/FFPE            34              IHC/PCR/WB        mRNA/Pr       NA         NA                         NA
  Satish K.2012           USA     Caucasian              MPM                   NA           TMA            75(62/13)           IHC+TMA            Pr          NA         NA                         NA
  Xu Z. 2010             China      Asian            Neuroblastom          INSS I--IV       FFPE              142                IHC              Pr          NA         NA                         NA
  Michael G.B.2008        USA     Caucasian              NHL                Cs I--IV        Fre            69(44/25)          IHC/PCR/WB        mRNA/Pr      MGB≥2       NA                         NA
  Korey R. J. 2005        USA     Caucasian   NSCLC/Breast/Ov/Ut/Rect/SI       NA        FFPE/cDNA     20/40/14/40/16/2     IHC/cDNA probe       mRNA         NA         NA                         NA
  Bernard M. 2010       France    Caucasian            prostate            Ps 2b--3b      Fre/TMA            30/88              Ra/IHC        Activity/Pr     NA         NA                         NA
  Nunes J. 2012           UK      Caucasian            Prostate                NA           RBC           108(88/20)              Ra           Activity       NA         NA                         NA
  Leyre B. 2012         France    Caucasian            prostate                NA            \-           139/13pair           IHC/ Ra         Activity      IRS≥3       NA                         NA
  Liu G.L. 2010          China      Asian                SGC                Cs I--IV      Fre/FFPE        161(159/2)          IHC/PCR/WB        mRNA/Pr      Ws≥6       120 m     5S 2.89(1.56--5.34) OS 2.02(0.92--4.43)
  Guan H.Y. 2011         China      Asian              Thyroid              Cs I--IV        FFPE           58(42/16)             IHC              Pr          NA         NA                         NA
  Yue Z.W. 2012          China      Asian                TSCC               Cs I--IV        FFPE              126                IHC              Pr         Ws≥2        NA                         NA

**Abbreviations** FFPE: formalin fixed paraffin embedded; TMA: tissue microarrays; ICH: Immunohistochemistry; PCR: polymerase chain reaction; WB: western-blot; Ra: radioassay; Pr: protein; HNSCC: Head and neck squamous cell carcinoma; TSCC: Tongue squamous cell carcinoma; MPM: Malignant pleural mesothelioma; NHL: non-Hodgkin lymphomas; SGC: salivary gland carcinoma; Ov: Ovary; Ut: Uterus; Rect: Rectum; SI: Small intestine; OS: Overall survival; 5S: Five-year survival rate; Cs: Clinical stage; Hg: Histological grade; SBR: Scarff-Bloom-Richardson; Ds: Dukes\' stage; INSS: International Neuroblastoma Staging System; Ps: Pathological stage; IRS; Immunoreactivity scores; AP: Affymetrix Probeset; Hs: Histoscore method; Ws: Weighted score; MGB: hematopathologist; NA: not available.

SK1 expression in cancer and non-cancer tissues {#s3b}
-----------------------------------------------

Initially, we assessed the association between SK1 positivity/high expression and cancer. Thirteen studies in which SK1 expression was detected by IHC were included in this meta-analysis. Statistical heterogeneities were found in the subgroup analyses, except for that of adjacent non-cancer tissues versus benign tissues; therefore, a random-effect model was applied. The results demonstrated that significant differences in SK1 positivity/high expression rates were found between cancer and non-cancer tissues, cancer and adjacent non-cancer tissues, cancer and benign tissues, and adjacent non-cancer and benign tissues (all P \< 0.0001); the respective OR (95% CI) were 11.86 (6.37--22.08), 6.66 (3.47--12.79), 11.94 (6.65--21.46), and 2.68 (1.70--4.20). SK1 positivity/high expression is considered to associate with cancer ([Figure 2](#pone-0090362-g002){ref-type="fig"}). To prove the robust results regarding this association between SK1 expression and cancer, a sensitivity analysis was conducted by omitting some of the obviously different studies until an acceptable heterogeneity level was reached ([Table 2](#pone-0090362-t002){ref-type="table"}). In the absence of significant heterogeneity (P \> 0.1, *I* ^2^ \< 50%) among the studies, a fixed model was adopted and the association was still observed. Therefore, we think that our results were stable and credible.

![Forest plot of SK1 positivity and high expression in cancer and on-cancer tissues.\
A subgroup analysis and random-effect model were used. The squares and horizontal lines correspond to the study-specific OR and 95% CI. The diamond represents the summary OR and 95% CI.](pone.0090362.g002){#pone-0090362-g002}

10.1371/journal.pone.0090362.t002

###### Sensitivity analysis of high heterogeneity outcomes in meta-analysis.

![](pone.0090362.t002){#pone-0090362-t002-2}

                                                                                                                         Experimental   control   heterogeneity         Outcomes                                        
  ---------------------- ---------------------------------------------------------------------------------------------- -------------- --------- --------------- ----- ---------- ------ ------- ---------------------- -----------
  cancer vs non-cancer    [@pone.0090362-Kawamori1], [@pone.0090362-Yi1], [@pone.0090362-Zhuge1], [@pone.0090362-Yue1]       404          548          236        553     26%      0.21   Fixed    5.32 (3.91, 7.24)     \<0.0001
  cancer vs adjacent                               [@pone.0090362-Shan1], [@pone.0090362-Su1]                                252          345          23         106     30%      0.22   Fixed   15.96 (8.42, 30.26)    \<0.00001
  cancer vs benign                                 [@pone.0090362-Su1], [@pone.0090362-Liu3]                                 275          388          20         150      0%      0.62   Fixed   30.15 (15.23, 59.70)   \<0.00001

SK1 mRNA and protein expression level changes in cancers {#s3c}
--------------------------------------------------------

Seventeen studies reported SK1 mRNA expression levels, and 12 studies reported SK1 protein expression levels. The sample sizes in these studies ranged from 4 to 95 cases. All outcomes indicated an increasing trend of SK1 mRNA and protein expression levels in cancer tissues. When the SK1 expression levels in normal tissues were assumed to be 1, the mRNA level increases ranged from 1.48-fold in uterine cancer to 7.86-fold in salivary gland carcinoma, and the protein level increases ranged from 1.45-fold in non-Hodgkin's lymphoma to 8.88-fold in gastric cancer ([Figure 3](#pone-0090362-g003){ref-type="fig"}).

![SK1 mRNA and protein-level expression in cancers, compared with normal tissues, via RT-PCR (A) and western blot (B).\
SK1 expression levels in all normal tissues are assumed to be 1. Histograms symbolize the relative levels of SK1 protein or mRNA expression in different cancers.](pone.0090362.g003){#pone-0090362-g003}

SK1 positivity/high expression rates in cancers {#s3d}
-----------------------------------------------

Different cancer types present different rates of SK1 positivity/high expression. We calculated the SK1 positivity/high expression rates in various cancers, and these results are shown in [Table 3](#pone-0090362-t003){ref-type="table"}. The SK1 positivity/high expression rate in estrogen receptor-negative (ER−) breast cancers (58.7%) was higher than that in ER-positive (ER+) breast cancers (27.3%). The average positive rate in breast cancers was 31.1%. The lowest positive rate was found in breast cancer with unknown ER expression status, whereas the highest positive rate (82.2%) was found in tongue squamous cell carcinoma (TSCC; [Table 3](#pone-0090362-t003){ref-type="table"}). Because of the small sample size of the TSCC study (n = 45), selection or other biases would unavoidably affect the result.

10.1371/journal.pone.0090362.t003

###### SK1 positive/high expression in variety cancers and non-cancer tissues.

![](pone.0090362.t003){#pone-0090362-t003-3}

  Cancer types                Total   SK1 positive/high expression (%)
  -------------------------- ------- ----------------------------------
  ER+ breast cancer           2202               602(27.3)
  ER- breast cancer            812               477(58.7)
  Breast cancer(unknow)       1287               257(20.0)
  Breast cancer(total)        4301               1336(31.1)
  Salivary gland carcinoma     159                85(53.5)
  Esophageal cancer            136               110(80.9)
  Gastric Cancer               412               263(63.8)
  Colon cancer                 229               170(74.2)
  Prostate cancer              227               163(71.8)
  Glioma                       243               100(41.2)
  Neuroblastoma                142                73(51.4)
  Thyroid Cancer               42                 29(69.0)
  HNSCC                        18                 8(44.4)
  TSCC                         45                 37(82.2)
  Non-cancer tissues           750               255(34.0)

**Abbreviations** SGC: salivary gland carcinoma; HNSCC: Head and neck squamous cell carcinoma; TSCC: Tongue squamous cell carcinoma; NA: not available.

SK1 enzyme activity in cancer tissues {#s3e}
-------------------------------------

Four studies that measured SK1 enzyme activity were evaluated. One was excluded because the SK1 activity was measured in the blood [@pone.0090362-Nunes1]. A forest plot showed that the SMD (95% CI) were 3.27 (0.38--6.16), with P = 0.03 ([Figure 4](#pone-0090362-g004){ref-type="fig"}). One study by Leyre (2012) reported an obvious excess of SK1 enzyme activity levels, compared with the other 2 studies [@pone.0090362-Brizuela1]; the heterogeneity was so remarkable (P \<0.00001, I^2^ = 96%) that it could not be altered by omitting any single study from the sensitivity analysis; therefore, we cannot draw a firm conclusion regarding a relationship between SK1 activity and cancer.

![Forest plot of the association between SK1 enzyme activity and cancer tissues.\
A random-effect model was used. The pooled SMD is symbolized by a solid diamond at the bottom of the forest plot, the width of which represents the 95% CI.](pone.0090362.g004){#pone-0090362-g004}

Five-year and overall survival rates and SK1 expression in cancer tissues {#s3f}
-------------------------------------------------------------------------

The HR values, log\[HR\], and SE\[log(HR)\] were either obtained directly from study data or extracted from survival curves, according to the methods described by Parmar or Tierney [@pone.0090362-Parmar1], [@pone.0090362-Tierney1]. Generic inverse variance (IV) and subgroup analyses were adopted according to the types of cancer. As no significant heterogeneity was found, a fixed-effect model was used to perform the meta-analysis. The 5-year survival meta-analysis showed that in cancer patients, the HR of SK1 positivity/high expression was 1.86 (95% CI, 1.18--2.94) for breast cancer (P = 0.008), 1.58 (1.08--2.31) for gastric cancer (P = 0.02), and 2.68 (2.10--3.44) for other cancers (P \< 0.0001). The total HR among all the cancers was 2.21 (95% CI, 1.83--2.67; P \< 0.00001). SK1 positivity/high expression is thought to associate with a shorter 5-year survival duration in cancer patients ([Figure 5](#pone-0090362-g005){ref-type="fig"}). For overall survival, the HR was 2.09 (95% CI, 1.35--3.22) for breast cancer (P = 0.0009), 1.56 (1.08--2.25) for gastric cancer (P = 0.02), and 2.62 (2.05--3.35) for other cancers (P \< 0.00001). The total effect HR was 2.21 (95% CI, 1.83--2.66; P \<0.00001). These data imply that SK1 positivity/high expression is related to overall survival in various cancers ([Figure 6](#pone-0090362-g006){ref-type="fig"}).

![Forest plot of association between SK1 expression and 5-year survival.\
A subgroup analysis for different cancers and fixed-effect model were used. The squares and horizontal lines correspond to the study-specific HR and 95% CI. The areas of the squares reflect the weights (inverse of the variance). The diamond represents the summary HR and 95% CI.](pone.0090362.g005){#pone-0090362-g005}

![Forest plot of association between SK1 expression and overall survival.\
A subgroup analysis for different cancers and fixed-effect model were used. The squares and horizontal lines correspond to the study-specific HR and 95% CI. The areas of the squares reflect the weights (inverse of the variance). The diamond represents the summary HR and 95% CI.](pone.0090362.g006){#pone-0090362-g006}

Publication bias {#s3g}
----------------

Egger's test was performed to assess the publication bias in the literature. In a subgroup analysis of SK1 expression in cancer, adjacent non-cancer, and benign tissues, publication bias was found for cancer versus adjacent non-cancer (P = 0.009) and cancer versus benign tissues (P = 0.04); the funnel plot was not symmetrical. No publication bias was found for cancer versus non-cancer (P = 0.059) and adjacent non-cancer versus benign tissues (P = 0.176; [Figure 7](#pone-0090362-g007){ref-type="fig"}). This might be a limitation of our analysis because studies with null findings, especially those with small sample sizes, were less likely to be published. In addition, different test methods were used in these studies. No publication bias was found with regard to 5-year (P = 0.754) and overall survival (P = 0.175; [Figures 8](#pone-0090362-g008){ref-type="fig"} and [9](#pone-0090362-g009){ref-type="fig"}).

![Funnel plot for publication bias in an association analysis of SK1 expression among cancer, adjacent non-cancer, and benign tissues.\
Begg's linear regression test was used, and P = 0.059, 0.009, 0.040, and 0.176 in a subgroup analysis of SK1 positivity and high expression in cancer and non-cancer tissues, respectively ([Figure 2](#pone-0090362-g002){ref-type="fig"}).](pone.0090362.g007){#pone-0090362-g007}

![Funnel plot for publication bias regarding 5-year survival.\
Begg's linear regression test was used; P = 0.754.](pone.0090362.g008){#pone-0090362-g008}

![Funnel plot for publication bias regarding overall survival.\
Begg's linear regression test was used; P = 0.175.](pone.0090362.g009){#pone-0090362-g009}

Discussion {#s4}
==========

The lipid kinase SK1 is expressed extensively in human beings, mice, yeast, and plants and plays an important role in regulating the dynamic balance of the ceramide/S1P rheostat. SK1 overexpression or increased activity leads to S1P accumulation that in turn contributes to prosurvival and anti-apoptotic mechanisms, as well as cancer genesis, metastasis, and drug-resistance. In contrast, ceramide accumulation leads to pro-apoptotic, autophagic, and anti-survival effects. High SK1 expression was detected in many cancers, including those of the lung, breast, ovary, stomach, and kidney.

IHC of formalin-fixed, paraffin-embedded samples is among the most commonly used methods to detect SK1 expression. We evaluated the association of SK1 and different cancers and non-cancer tissues according to the IHC outcomes. In the subgroup and total effect analyses, SK1 positivity/high expression was significantly increased in cancer tissues, compared with non-cancer (adjacent and/or benign) tissues. The OR between cancer and adjacent tissues (2.68) was less than that between cancer and benign tissues (11.94). This finding demonstrates that the SK1 expression level gradually increased in benign, adjacent, and cancer tissues. This might indicate that SK1 expression is associated with degrees of pathological differentiation or heterogeneity in cancer. However, different IHC judgment criteria existed among these studies. Positive and negative were used to judge some, while others were graded according to signs (−, +, ++, and +++). In our meta-analysis, we used negative/low (including − and +) and positive/high (including ++ and +++) to assess SK1 expression in different tissues. That might be partly responsible for the heterogeneity.

When the mRNA and protein expression levels were detected via reverse transcriptase PCR or western blotting, the results were consistent. We found that the SK1 positive/high expression rates varied tremendously between different types of cancer (ranging from 20--82.2%). Differences in SK1 tissue distribution might be the main reason for this variation. Because the sample sizes and detection methods were different, the high heterogeneity prevented us from merging the studies to perform a meta-analysis.

Moreover, only 3 studies [@pone.0090362-Brizuela1], [@pone.0090362-Knapp1], [@pone.0090362-Malavaud1] reported SK1 enzyme activity, and the interstudy activity level gaps were very wide ([Figure 3](#pone-0090362-g003){ref-type="fig"}). In all the 3 studies, the radioassay method was used to detect SK1 activity. This gap might have been introduced by the operator or testing instrument. It might also have been caused by differences in cancer types. To obtain more accurate results, more studies and the evaluation of more samples of the same cancer type with identical detection methods are needed.

Regarding the survival analysis, the follow-up duration in these studies ranged from 30 months to 12 years. We used 5-year and overall survival to evaluate the correlation between SK1 expression and survival in cancer patients. Studies in which the follow-up time was ≥5 years were included in the 5-year survival analysis. Because the overall survival follow-up times differed, we could not acquire concrete data from some of the articles and instead extracted data from survival curves. Therefore, the outcomes might not be very accurate. However, we do not believe that this affected the total outcome.

In our study, SK1 expression was detected in 19 common types of cancer. Some of the more common cancers were the focus of more studies, including breast cancer, which was researched in 7 studies [@pone.0090362-Ruckhaberle1], [@pone.0090362-ErezRoman1], [@pone.0090362-Watson1], [@pone.0090362-Yi1], [@pone.0090362-Ohotski1], [@pone.0090362-Ohotski2], [@pone.0090362-Ruckhaberle2], and colon cancer, which was researched in 5 studies[@pone.0090362-Kawamori1], [@pone.0090362-Jing1], [@pone.0090362-Su1], [@pone.0090362-Liu3], [@pone.0090362-Rosa1]. Therefore, different cancers were represented unequally with respect to sample numbers. Meanwhile, the cancer tissue sample and control sample selection methods differed among different studies. In some studies, the cancer and control tissue samples were collected from different areas in the same patient, whereas in other studies, the samples were collected from different patients. Moreover, in these studies, different SK1 detection methods were used and cancer patients of different ethnicities were included. All of these could be sources of heterogeneity. Despite the heterogeneity that was observed in some subgroup analyses, the total outcomes were not affected by the sensitivity analysis.

There were some other limitations and potential biases in our meta-analysis. First, as few (\<3) studies regarding disease-specific survival (DSS) and disease-free survival (DFS) were included, we could not perform a meta-analysis of those variables, which are used to evaluate prognosis in cancer patients. Second, this meta-analysis did not discuss the associations between SK1 and ethnicity, tumor size, TNM stage, histological classification, pathological differentiation, lymphatic invasion, and metastasis, all of which are important clinical characteristics in cancer. In addition, only 1 or 2 studies were identified for some types of cancer, and as those sample sizes are insufficient, the associated biases might be remarkable.

In the individual papers, the SK1 expression were found in one or two kinds of cancers in each study. In our meta-analysis, we found that there were relationships between SK1 expression and various cancers, which may imply the possibility of using the SK1 level as the clinical biomarker of cancers.

Conclusion {#s5}
==========

Despite some limitations in this meta-analysis, our study still demonstrates that SK1 positivity/high expression is significantly associated with various types of cancers and reduced 5-year and overall survival. Because the SK1 positivity/high rates differ in different types of cancer, it is necessary to further explore whether SK1 might be a predictive biomarker of outcomes in cancer patients.
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